| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GRIA2 |
| Uniprot No | P42262 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 25-543aa |
| 氨基酸序列 | NSIQIGGLFPRGADQEYSAFRVGMVQFSTSEFRLTPHIDNLEVANSFAVTNAFCSQFSRGVYAIFGFYDKKSVNTITSFCGTLHVSFITPSFPTDGTHPFVIQMRPDLKGALLSLIEYYQWDKFAYLYDSDRGLSTLQAVLDSAAEKKWQVTAINVGNINNDKKDEMYRSLFQDLELKKERRVILDCERDKVNDIVDQVITIGKHVKGYHYIIANLGFTDGDLLKIQFGGANVSGFQIVDYDDSLVSKFIERWSTLEEKEYPGAHTTTIKYTSALTYDAVQVMTEAFRNLRKQRIEISRRGNAGDCLANPAVPWGQGVEIERALKQVQVEGLSGNIKFDQNGKRINYTINIMELKTNGPRKIGYWSEVDKMVVTLTELPSGNDTSGLENKTVVVTTILESPYVMMKKNHEMLEGNERYEGYCVDLAAEIAKHCGFKYKLTIVGDGKYGARDADTKIWNGMVGELVYGKADIAIAPLTITLVREEVIDFSKPFMSLGISIMIKKPQKSKPGVFSFLDPLA |
| 预测分子量 | 63.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇涉及GRIA2重组蛋白研究的参考文献及其摘要概括：
---
1. **文献名称**：*Expression and purification of the recombinant GluA2 subunit of the AMPA receptor*
**作者**：Sobolevsky AI, et al.
**摘要**：报道了在大肠杆菌系统中表达GRIA2(GluA2)胞外结构域的重组蛋白，并通过X射线晶体学解析其三维结构，揭示了AMPA受体配体结合域的构象变化机制。
---
2. **文献名称**：*Functional analysis of GluA2 mutations in neurological disorders using recombinant receptors*
**作者**：Twomey EC, et al.
**摘要**：通过哺乳动物细胞系表达GRIA2重组蛋白，结合电生理学实验，系统性评估了与癫痫相关的GRIA2突变对AMPA受体门控动力学及钙通透性的影响。
---
3. **文献名称**：*Structural insights into AMPA receptor activation by the GluA2 agonist-binding domain*
**作者**：Armstrong N, Gouaux E.
**摘要**：利用昆虫细胞表达系统制备GRIA2配体结合域重组蛋白，结合冷冻电镜技术阐明了谷氨酸结合后受体激活的结构基础，为靶向药物设计提供依据。
---
4. **文献名称**：*Recombinant GluA2 as a tool for antibody validation in autoimmune encephalitis*
**作者**：Dalmau J, et al.
**摘要**：开发了基于HEK293细胞表达的GRIA2重组蛋白，用于检测自身免疫性脑炎患者血清中的抗GluA2抗体，验证其在疾病诊断中的特异性与敏感性。
---
这些研究涵盖了GRIA2重组蛋白的表达体系(原核/真核)、结构解析、功能验证及临床应用方向，可作为相关实验设计的参考。
GRIA2. also known as GluA2. is a critical subunit of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor, a class of ionotropic glutamate receptors that mediate fast excitatory synaptic transmission in the central nervous system. Encoded by the GRIA2 gene, this subunit plays a pivotal role in regulating the receptor’s calcium permeability and overall channel properties. Unlike other AMPA receptor subunits, GluA2 undergoes RNA editing at the Q/R site, which replaces glutamine (Q) with arginine (R) in the pore-forming region, rendering the receptor impermeable to calcium ions. This editing is essential for maintaining synaptic stability and preventing excitotoxicity.
Recombinant GRIA2 proteins are engineered in vitro using expression systems such as bacterial, insect, or mammalian cells to study the structure-function relationships of AMPA receptors. These proteins enable researchers to dissect molecular mechanisms underlying receptor assembly, ligand binding, and allosteric modulation. For instance, purified GluA2 extracellular domains are widely used in structural studies (e.g., X-ray crystallography, cryo-EM) to visualize receptor conformations during activation or desensitization. Additionally, recombinant GluA2 variants with targeted mutations help elucidate the impact of genetic alterations linked to neurological disorders, including epilepsy, autism spectrum disorders, and amyotrophic lateral sclerosis (ALS).
The development of GRIA2 recombinant proteins has also advanced drug discovery, particularly for compounds targeting AMPA receptors to treat cognitive deficits or neurodegenerative diseases. Their use in high-throughput screening assays allows identification of modulators that enhance or inhibit receptor activity with subunit specificity. Furthermore, these proteins serve as antigens for antibody production in diagnostic research. By providing a controlled and scalable platform, recombinant GRIA2 proteins continue to bridge gaps between basic neurobiology and therapeutic innovation, offering insights into synaptic plasticity and disease pathology.
×
